|
||
|
Venture capital firms and funds in Europe 128 Venture Capital Group 3i Venture Capital Accuitive Medical Acer Venture Capital Act Venture Capital Ltd Adelaide Venture Capital Email ADS Ventures Boston Advantages Of Venture Capital Advent Venture Capital Agio Capital Alabama Venture Capital Alaska Venture Capital All Stages Venture Capital American Venture Capital Analysis Venture Capital Analyze Venture Capital Angel Capital Appraisal Venture Capital Arch Venture Capital Argentina Venture Capital Arizona Venture Capital Arkansas Venture Capital Arrowpath Venture Capital Assess Venture Capital Assessment Venture Capital Atlas Venture Capital ATV Venture Capital Aurora Fund Australia Venture Capital Austria Venture Capital Automotive Venture Capital AZ Venture Capital VCgate More Venture Capital Terms and Topics
-
RenaMed Biologics Secures $40 Million in Private Equity Financing
September 7th, 2006 No comments
Funds to Advance Clinical Development of Renal Bio-Replacement Therapy for the Treatment of Acute Renal Failure
RenaMed Biologics, Inc. announced recently that it has successfully completed a $40 million mezzanine financing. The funds will be used to continue the clinical development of the company’s Renal Bio-Replacement Therapy for Acute Renal Failure, as well as support its move to a new headquarters and manufacturing facility in Westborough, MA.
TVM Capital and Lurie Investments co-led the financing and were joined by several new investors, including MDS Capital, Merlin BioMed Group, and TSC BioVenture Capital Corporation. Existing investors who also participated in this round include: Apjohn Ventures Fund, BD Ventures (Becton Dickinson), Bio*One Capital (Singapore), and NorthCoast Technology Investors. As part of this financing, RenaMed expanded its Board of Directors to include Dr. Gert Caspritz, general partner of TVM Capital, and Gerry Brunk, venture partner of MDS Capital.
“This was a very successful financing round which exceeded our objectives and brought several new strong life science investors into RenaMed,” said Greg Phelps, Chairman and CEO of RenaMed. “I am encouraged by the positive financial market response to our lead product and progress. The funds raised enable us to drive the clinical development of our Acute Renal Failure program through Phase 2 this year and into Phase 3 next year, complete the build-out and commissioning of manufacturing in our Westborough, MA facility, and expand investment in other programs.”
RenaMed is developing Renal Bio-Replacement Therapy (RBT) to temporarily replace lost kidney functions in ICU patients with Acute Renal Failure (ARF), as a bridge to survival and full recovery. RBT is administered ex vivo using physiologically active human renal epithelial cells incorporated in a hollow-fiber dialysis cartridge. RBT works in conjunction with current filtration therapies and fits into standard hospital ICU procedures. In 2005 RenaMed entered into a strategic collaboration with Genzyme Corporation to jointly develop RBT for ARF, and the product is currently in a second Phase 2 trial.
“RenaMed has demonstrated significant progress in the development of its Renal Bio-Replacement Therapy for the treatment of Acute Renal Failure,” said Dr. Gert Caspritz, general partner of TVM Capital. “ARF is a severe problem with an extremely high mortality rate and currently no effective treatment options. However, RenaMed has shown exciting Phase 2 clinical results in a randomized and well-designed study . Led by a very strong management team, the company has built the development and manufacturing expertise necessary for success and has put in place a strategic collaboration with Genzyme. It is the strength of these accomplishments and prospect for success that made this a compelling, strategic investment for TVM Capital.”
Lehman Brothers of New York served as the placement agent for the financing.
Leave a reply
Latest Headlines:
Friday August 31, 2012
Zscaler Secures $38 Million Investment Round
Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.
Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects
Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding
Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies
Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains
Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster
Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility